COOL BRIDGE Study
Research type
Research Study
Full title
Induction of Therapeutic Hypothermia and Temperature Management with Transnasal Evaporative Cooling from admission to the Critical Care Unit following Out of Hospital Cardiac Arrest
IRAS ID
130213
Contact name
Jeff Keep
Contact email
Sponsor organisation
King's College Hospital NHS Foundation Trust
Research summary
Research Question
To explore the feasibility and proficiency of very early brain cooling following survival after cardiac arrest (the heart stopping), and continuation of targeted temperature management using the RhinoChill Intranasal cooling device and low-flow adaptor.Following a cardiac arrest (the heart stopping), there is strong evidence to suggest that to minimise brain damage, improve survival and improve quality of life, patients should be cooled to between 32 and 34 degrees Celsius (therapeutic hypothermia) for 12 to 24 hours. It is generally accepted that the earlier a patient is cooled, the better the potential outcome will be.
Therapeutic hypothermia is recommended as the standard of care by the European Resuscitation Council for patients following cardiac arrest.
This trial seeks to enroll 20 patients who have had their hearts started again following cardiac arrest, and who remain unconscious, to have therapeutic hypothermia started with the RhinoChill device. These patients will have their brain temperature rapidly cooled to 33.0oC with the RhinoChill device and then their temperature will be maintained between 32 and 34.0oC using the low flow adaptor and varying flow rates of the RhinoChill until the patient arrives into the Critical Care Department. Temperature management with the RhinoChill will be maintained throughout required scans, coronary interventions or other emergency investigations or treatments required prior to arrival in Critical Care.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
14/EE/0085
Date of REC Opinion
21 Mar 2014
REC opinion
Favourable Opinion